3LCO | date | ![]() |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | |||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | |||||||||||||
ligand | LC0 BindingDB | enzyme |
| ||||||||||||
Gene Ontology ![]() |
| ||||||||||||||
Primary reference | Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode., Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A, Bioorg Med Chem Lett. 2010 Mar 1;20(5):1543-7. Epub 2010 Jan 21. PMID:20137931 |
Data retrieval |
![]() |
View 3LCO in 3D |
![]() |
Structure-derived information |
Sequence-derived information |
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |